

CONFERENCE PROGRAM AND SCHEDULE

Wednesday, September 16, 2015

1:30 p.m.-1:35 p.m.

Welcome

Metropolitan Ballroom

Jill O'Donnell-Tormey, Cancer Research Institute, New York, NY

1:35 p.m.-2:05 p.m.

Keynote Address

Metropolitan Ballroom

T cells as a drug for the personalized immunotherapy of cancer

Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

2:05 p.m.-4:05 p.m.

Plenary Session 1: Immune Regulation of T-Cell Responses/Evolving Concepts in Cancer Immunology

Metropolitan Ballroom

Session Chairperson: James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

2:05 p.m. Chairperson perspective: Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for a cure
James P. Allison

2:15 p.m. Biology of the PD-1 pathway
Arlene H. Sharpe, Harvard Medical School, Boston, MA

2:45 p.m. Antitumor activity of immunomodulatory antibodies
Alan Korman, Bristol-Myers Squibb, Redwood City, CA

3:15 p.m. The interplay between L-arginine metabolism and adoptive immunity in cancer
Vincenzo Bronte, Venetian Institute of Molecular Medicine, Padova, Italy

3:45 p.m. Tumor-derived CD103+ dendritic cells carry antigen to the tumor-draining lymph node and are essential for CD8+ T-cell priming*
Edward Roberts, University of California, San Francisco, CA

4:05 p.m.-4:35 p.m.

Refreshment Break

Lenox Ballroom, Empire Ballroom, and Metropolitan Ballroom Foyer

4:35 p.m.-6:35 p.m.

Plenary Session 2: Tumor Antigens for Targeting: Insights from Genomics

Metropolitan Ballroom

Session Chairperson: Christoph Huber, Johannes Gutenberg University Mainz Medical Center, Mainz, Germany

4:35 p.m. Chairperson perspective
Christoph Huber

4:45 p.m. Personalizing cancer immunotherapy
Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO

5:15 p.m. Targeting the mutanome for individualized cancer immunotherapy
Ugur Sahin, TRON Translational Cancer Center-Johannes Gutenberg University; BioNTech Biopharmaceutical New Technologies Corporation, Mainz, Germany

5:45 p.m. Impact of the immunogenic landscape of cancers on immunotherapy
Hans-Georg Rammensee, University of Tuebingen, Tuebingen, Germany

6:15 p.m. Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens*
Todd D. Prickett, National Cancer Institute, Bethesda, MD

6:45 p.m.-8:45 p.m.

Reception

Central Park and Lenox Ballroom

Poster Session A

Empire Ballroom

Biomarkers

Clinical Trials of Cancer Immunotherapies

Drug Development

*Proffered presentation

Immune Regulation of T-Cell Responses/Evolving Concepts in Cancer Immunology

Microbiome

Other

Preclinical Models

Tumor Antigens for Targeting: Insight from Genomics

Tumor Microenvironment and Cross Talk with the Immune System

Thursday, September 17, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast

Central Park, Lenox Ballroom, and New York Ballroom Foyer

7:45 a.m.-8:35 a.m.
The 2015 William B. Coley Lectures

Metropolitan Ballroom

7:45 a.m. Alexander Rudensky, Memorial Sloan Kettering Cancer Center, New York, NY

8:10 a.m. Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA

8:35 a.m.-12:05 p.m.
Plenary Session 3: Clinical Trials of Cancer Immunotherapies, Part 1

Metropolitan Ballroom

Session Chairperson: Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA

8:35 a.m. Combination checkpoint blockade
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research, New York, NY

9:05 a.m. Treating the tumor and treating the host
Ronald Levy, Stanford University School of Medicine, Stanford, CA

9:35 a.m. Designing immunostimulatory mAb to promote anticancer immunity
Martin J. Glennie, University of Southampton, Southampton, United Kingdom

10:05 a.m. Refreshment Break
Central Park, Lenox Ballroom, and New York Ballroom Foyer

10:35 a.m. Engineered T cells for cancer therapy
Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

11:05 a.m. Engaging T cells against cancer: BLINCYTO® and beyond – the BiTE® platform
Dirk Nagorsen, Amgen, Inc., Thousand Oaks, CA (not eligible for CME credit)

11:35 a.m. Combinatorial modalities with immune checkpoint blockade
F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA

12:05 p.m.-1:35 p.m.
Lunch Session: Roundtable Discussion: The Regulatory Landscape for Cell and Gene Therapy
Metropolitan Ballroom

Session Chairperson: Cedrik Britten, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

Lunch will be served.

Discussants:

Gwendolyn Binder-Scholl, Adaptimmune LLC, Oxon, United Kingdom

Cedrik Britten

Elma Hawkins, Lion Biotechnology, New York, NY

Robert Hawkins, Cancer Research UK Manchester Institute, Manchester, United Kingdom

Thomas Hinz, Paul-Ehrlich-Institut, Langen, Germany

Laura Johnson, University of Pennsylvania, Philadelphia, PA

Carl June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Michael Kalos, Lilly, New York, NY

David Lebwohl, Novartis Pharmaceuticals Corporation, Florham Park, NJ

Celia Witten, Center for Biologics Evaluation and Research, FDA, Rockville, MD

*Proffered presentation

CONFERENCE PROGRAM AND SCHEDULE

12:05 p.m.-1:35 p.m.

Lunch

Central Park and Lenox Ballroom

1:45 p.m.-5:15 p.m.

Plenary Session 4: Tumor Microenvironment and the Cross Talk Between Immune/Inflammatory Cells and the Tumor Stroma, Matrix, and Vasculature

Metropolitan Ballroom

Session Chairperson to be announced

1:45 p.m. Chairperson perspective

Speaker to be announced

1:55 p.m. Inflammation and cancer: Immune cells as targets for anticancer therapy

Lisa Coussens, Oregon Health & Science University, Portland, OR

2:25 p.m. Therapy-induced anticancer immunosurveillance: The example of successful chemotherapies

Guido Kroemer, Cordeliers Research Center (INSERM) - Institut Gustave-Roussy, Villejuif, France

2:55 p.m. Tumor stroma: Immunomodulatory functions and a target of immunotherapy

Ellen Puré, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA

3:25 p.m. Refreshment Break

Central Park, Lenox Ballroom, and New York Ballroom Foyer

3:55 p.m. Regulation of T-cell homing in tumors

George Coukos, Ludwig Center for Cancer Research-University of Lausanne, Lausanne, Switzerland

4:25 p.m. Cancer subtypes and their immune microenvironments

Wolf Herve Fridman, Cordeliers Research Center (INSERM), Paris, France

4:55 p.m. Hypoxia is an essential driver of immune suppression in the tumor microenvironment*

Michael A. Curran, The University of Texas MD Anderson Cancer Center, Houston, TX

*Proffered presentation

Friday, September 18, 2015

7:00 a.m.-8:00 a.m.

Continental Breakfast

Central Park, Lenox Ballroom, and New York Ballroom Foyer

7:00 a.m.-8:00 a.m.

Meet the Editors

Central Park

Cancer Immunology, Immunotherapy

Graham P. Pawelec, Editor-in-Chief

Suzanne Ostrand-Rosenberg, Editor-in-Chief

Cancer Immunology Research

Robert D. Schreiber, Editor-in-Chief

Philip D. Greenberg, Editor-in-Chief

Linda J. Miller, Executive Editor

Onc Immunology

Guido Kroemer, Editor-in-Chief

Laurence Zitvogel, Editor-in-Chief

Lorenzo Galluzzi, Editor-in-Chief

8:00 a.m.-9:40 a.m.

Plenary Session 5: Immunotherapy of Persistent Viral Infections and Virus-1 Induced Cancers

Metropolitan Ballroom

Session Chairperson: Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands

8:00 a.m. Chairperson perspective

Cornelis J.M. Melief

8:10 a.m. Properly timed chemo-immunotherapy of cancer

Sjoerd Henricus van der Burg, Leiden University Medical Center, Leiden, The Netherlands

8:40 a.m. Immunotherapy with virus-specific T cells

Helen Heslop, Baylor College of Medicine, Houston, TX

9:10 a.m. T-cell memory and exhaustion

Rafi Ahmed, Emory University, Atlanta, GA

9:40 a.m.-10:10 a.m.

Refreshment Break

Metropolitan East and West Foyer

10:10 a.m.-12:40 p.m.

Plenary Session 6: Biomarkers

Metropolitan Ballroom

Session Chairperson: Ira Mellman, Genentech, Inc.,
South San Francisco, CA

10:10 a.m. Chairperson perspective: Biomarkers and mechanism in immunotherapy

Ira Mellman

10:40 a.m. Immune checkpoint therapy: Immune monitoring on presurgical and tissue-based clinical trials

Padmanee Sharma, The University of Texas MD
Anderson Cancer Center, Houston, TX

11:10 a.m. Antigenome and immune contexture in cancer

Jerome Galon, INSERM, Paris, France

11:40 a.m. Genomic assessment of tumor immune profiles

Christian Ottensmeier, University of
Southampton, Southampton, United
Kingdom

12:10 p.m. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner

Rikke B. Holmgaard, Memorial Sloan Kettering
Cancer Center, Ludwig Cancer Research,
New York, NY

12:40 p.m.-2:10 p.m.

Lunch Session: Imaging and Targeting of the Antitumor Response

Metropolitan Ballroom

12:55 p.m. Immunological insights from tracking dynamic cellular behavior in lymph nodes and tissues

Alex Yee-Chen Huang, Case Western Reserve
University School of Medicine, Cleveland, OH

1:20 p.m. Towards synthetic immune cells for cancer immunotherapy

Carl G. Figdor, Nijmegen Centre for
Molecular Life Sciences (NCMLS), Nijmegen,
The Netherlands

1:45 p.m. Imaging immunity: Creating a quantitative spatiotemporal understanding of host defense and antitumor responses

Ronald N. Germain, National Institute of Allergy
and Infectious Disease, NIH, Bethesda, MD

12:40 p.m.-2:10 p.m.

Lunch

Central Park and Lenox Ballroom

2:25 p.m.-4:25 p.m.

Concurrent Session 1: Microbiome

Room TBD; see program addendum

Session Chairperson to be announced

2:25 p.m. Chairperson perspective

To be announced

2:35 p.m. Gut microbiota regulates anticancer immune responses

Laurence Zitvogel, Gustave Roussy Cancer
Center, Villejuif, France

3:05 p.m. Commensal microorganisms and polymorphic mucosal surfaces determine the evolution of distal metastatic tumors

Jose R. Conejo-Garcia, The Wistar Institute,
Philadelphia, PA

3:35 p.m. Biofilms, genetics, and colon cancer

Cynthia L. Sears, Johns Hopkins University,
Baltimore, MD

4:05 p.m. Tracking microbial sensing in colorectal cancer using bioorthogonal click chemistry*

Jason Hudak, Harvard Medical School,
Boston, MA

*Proffered presentation

CONFERENCE PROGRAM AND SCHEDULE

2:25 p.m.-4:25 p.m.

Concurrent Session 2: Companion Diagnostics: Assay Harmonization

Room TBD; see program addendum

Session Chairperson: Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

2:25 p.m. Introduction

Axel Hoos

2:35 p.m. Abigail McElhinny, Ventana Medical Systems, Inc., Tucson, AZ

2:45 p.m. Robert A. Anders, Johns Hopkins University School of Medicine, Baltimore, MD

3:05 p.m. Paul Tume, UCLA Medical Center, Los Angeles, CA

3:25 p.m. Kenneth Bloom, GE Healthcare, Aliso Viejo, CA

3:45 p.m. Panel Discussion

Robert A. Anders

Kenneth Bloom

Axel Hoos

Ian McCaffery, Genentech, South San Francisco, CA

Abigail McElhinny

Jim Novotny, Bristol-Myers Squibb, Princeton, NJ

Reena Philip, Food and Drug Administration

Center for Devices and Radiological Health,

Silver Spring, MD

Dave Stanforth, Dako North America - Agilent

Technologies, Carpinteria, CA

Paul Tume

4:45 p.m.-6:45 p.m.

Reception

Central Park and Lenox Ballroom

Poster Session B

Empire Ballroom

Companion Diagnostics: Assay Harmonization

Drug Development

Imaging and Targeting of the Antitumor Response

Immune Regulation of T-Cell Responses/Evolving Concepts in Cancer Immunology

Immunotherapy of Persistent Viral Infections and Virus-1 Induced Cancers

Preclinical Models

Trials in Progress (promising ongoing trials or unique trial designs that have not yet yielded results)

Tumor Microenvironment and Cross Talk with the Immune System

Saturday, September 19, 2015

7:00 a.m.-8:00 a.m.

Continental Breakfast

Central Park, Lenox Ballroom, and New York Ballroom Foyer

8:00 a.m.-10:00 a.m.

Concurrent Session 3: Preclinical Models

Room TBD; see program addendum

Session Chairperson: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

8:00 a.m. Chairperson perspective

Philip D. Greenberg

8:10 a.m. Modeling combination immunotherapy studies on CNS melanoma

Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

8:40 a.m. Designing combination immunotherapies to drive synergistic innate and adaptive antitumor immunity

Darrell J. Irvine, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA

9:10 a.m. Engineered T-cell receptor-based therapy of pancreatic ductal adenocarcinoma

Ingunn M. Stromnes, Fred Hutchinson Cancer Research Institute, University of Washington, Seattle, WA

*Proffered presentation

9:40 a.m. TGF-beta1 primed myeloid derived suppressor cells decrease tumor growth and lose their ability to inhibit T-cell proliferation via iNOS downregulation*

Padmini Jayaraman, Baylor College of Medicine, Houston, TX

8:00 a.m.-10:00 a.m. Concurrent Session 4: Drug Development: Immuno-Oncology Trial Design

Room TBD; see program addendum

Session Chairperson: Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

8:00 a.m. PD-1 directed antibody: A broad-based antineoplastic therapy

Roy Baynes, Merck Research Laboratories, Rahway, NJ

8:30 a.m. Title to be announced

Daniel S. Chen, Genentech, Inc., South San Francisco, CA

9:00 a.m. Title to be announced

Tai-Tsang Chen, Bristol-Myers Squibb, Wallingford, CT

9:30 a.m. Title to be announced

Axel Hoos

10:00 a.m.-10:30 a.m. Refreshment Break

Central Park and Lenox Ballroom

10:30 a.m.-1:00 p.m. Plenary Session 7: Clinical Trials of Cancer Immunotherapies, Part 2

Metropolitan Ballroom

Session Chairperson: Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

10:30 a.m. Mechanisms of protective tumor immunity

Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA

11:00 a.m. Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome

Jolanda deVries, Centre for Molecular Life Sciences, Nijmegen, The Netherlands

11:30 a.m. Prospect of a vaccine to prevent cancer in BRCA1-2 mutation carriers

Robert H. Vonderheide

12:00 p.m. Towards implementation of T-cell therapy in pancreatic cancer

Rienk Offringa, Deutsches Krebsforschungszentrum, Heidelberg, Germany

12:30 p.m. Nonviral gene transfer to redirect T-cell specificity

Laurence J.N. Cooper, The University of Texas MD Anderson Cancer Center, Houston, TX

1:00 p.m. Departure

*Proffered presentation